 |
| Interventional Oncology Ablation Market |
To develop and implement a novel Interventional Oncology Ablation Market for the treatment of cancer, researchers and key companies in the market are focused on substantial research and development activities.
The interventional Oncology Ablation Market has become a safe and painless process as a consequence of continued research and development, particularly due to excellent results both during and after the procedure.
Furthermore, as the healthcare sector across the world becomes more conscious, cancer ablation is growing more popular for many forms of cancer, such as liver cancer, kidney cancer, and so on, as one of the most popular cancer therapy methods.
In a pilot investigation, researchers from the University Of Missouri School Of Medicine discovered a therapeutic combination in December 2020 that greatly reduced tumor development and extended the life span of mice with liver cancer.
This discovery could pave the way for a novel therapeutic strategy for one of the world's leading causes of cancer-related death.
It's an integrated therapy that combines the chemotherapeutic medicine sunitinib with minimally invasive radiofrequency ablation (RFA).
The development of a successful sunitinib and RFA combination therapy is a significant contribution to the field of liver cancer treatment, and it can be promptly translated into practical applications because both sunitinib and RFA are FDA-approved and widely available cancer medicines.
In 2020, the global interventional oncology ablation market is predicted to be worth US$ 453.1 million, growing at a CAGR of 7.8% over the forecast period (2020-2027).
Over the forecast period, the market is expected to increase due to key companies' increasing adoption of inorganic growth tactics.
Because major market players are focusing on inorganic growth strategies such as acquisitions, partnerships, and agreements to strengthen their product portfolio and presence in the global market, the interventional oncology ablation market is expected to offer lucrative opportunities shortly.
For example, in January 2019, Medtronic agreed to purchase Epix Therapeutics, a firm that manufactures catheter-based systems for the treatment of patients with atrial fibrillation.
The company's cardiac ablation portfolio is likely to grow as a result of the acquisition.
Furthermore, Boston Scientific agreed to buy Criterion Medical in July 2018, a firm that created a single-shot cryoablation platform for the treatment of atrial fibrillation.
The former company will be able to provide geothermal and radiofrequency (RF) single-shot, balloon-based ablation therapies as a result of the transaction.
0 Comments